Skip navigation

Anti-Bribery and Anti-Corruption • Third-Party Due Diligence • Regional Transparency Initiatives • Incorporating a Culture of Ethics

May 28-29, 2019
  • Mexico City, Mexico

Pharmaceutical, biotech and medical device companies in Latin America are stepping up to combat bribery and corruption challenges. In an era of emerging compliance risks and political unrest, it is critical that life sciences organizations develop robust and tailored third-party and distributor management programs along with continuous risk-based audition and monitoring of third-parties.

Join CBI this May to strengthen compliance programs, increase transparency and commit to a culture of ethics.

Program Highlights Include:

  • Break down recent investigations and determine impact on regional enforcement trends
  • Analyze how Sunshine Act and other U.S. regulations influence health law in Latin America
  • Examine strategies to communicate the importance of adhering to international compliance laws
  • Gain insight on advancements in data analytics and applications within Latin American compliance programs to improve efficiency and efficacy
  • Mitigate cross-border risks and maximize HCP relationships
  • Overcome FMV and transparency reporting challenges in HCP interactions
PREVIOUS ATTENDEE ACCLAIM
FROM CBI’S PCC SERIES:

Pharmaceutical Compliance Congress Latin America

Anti-Bribery and Anti-Corruption • Third-Party Due Diligence • Regional Transparency Initiatives • Incorporating a Culture of Ethics

Pharmaceutical, biotech and medical device companies in Latin America are stepping up to combat bribery and corruption challenges. In an era of emerging compliance risks and political unrest, it is critical that life sciences organizations develop robust and tailored third-party and distributor management programs along with continuous risk-based audition and monitoring of third-parties.

Join CBI this May to strengthen compliance programs, increase transparency and commit to a culture of ethics.

Program Highlights Include:

  • Break down recent investigations and determine impact on regional enforcement trends
  • Analyze how Sunshine Act and other U.S. regulations influence health law in Latin America
  • Examine strategies to communicate the importance of adhering to international compliance laws
  • Gain insight on advancements in data analytics and applications within Latin American compliance programs to improve efficiency and efficacy
  • Mitigate cross-border risks and maximize HCP relationships
  • Overcome FMV and transparency reporting challenges in HCP interactions
PREVIOUS ATTENDEE ACCLAIM
FROM CBI’S PCC SERIES: